{"_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgN7fv-cKDA","lastupdate":"2022-12-20T00:00:00.000Z","update_date":"2022-12-20T00:00:00.000Z","lastModified":"Feb 1, 2022","active":1,"confidence_score":89,"confidence_score_reason":"video or image, markets, not claimed","urlname":"cell-cure-neurosciences","minimal_profile":null,"status":"","fullstatus":"","acquired":0,"hide_reason":null,"hide_reason_data":null,"hide_reasons":[{"id":"8257rxn4P8EFQOmS5hAAauHyYMhhxrA5u6yWX4XUShpybX3AMNo3Y9","reason":"Pending approval - External entity"},{"id":"aOIaOiiqfpA8UMw6VCTh8ueRmkG3lzDy1NGqEOaJbe11OrCzMTCCd6","reason":"The company is a service provider"},{"id":"ddgjKuc3GgH8E5UehSVJviRl471BCajL1plO8HtGoOojy2NivYqQ7x","reason":"Owner asked to delete"},{"id":"EjOKM211H1ira9J63oaGPuUxvr7Oba55TZo3NWsFO5uhbNu7o4x4zD","reason":"The company is not Israeli"},{"id":"J7fQJtnT3GdWWSE3MD8rzaW65LJ4jEIKxSZnneQiReONdZjG3zIqWe","reason":"Owner asked to hide in the meantime"},{"id":"NxlAC3ReFb5ksiYNLp2FnUyluoJzwRCYfcF7xpTZaPM53SdWQ5kv0B","reason":"Pending approval"},{"id":"RhC1tlwXzioK0MfzBII3H2wepEfQOfKVktmdwqeqTJjGi3ZaBWUqZo","reason":"The company is not innovative"},{"id":"S0Ed46vNI6vZYVxLedANWGjas23K6hY0QdsCtiGYL7lshqIEdLV3sA","reason":"The company ceased operations in Israel"},{"id":"VTANq7bEvlsEcPjp0ghelXfShaCosgndONGjgU730aAOxXtaDIF5j3","reason":"This is a product of an existing company"}],"type":"Startup","logokey":"$YN0LZm3MrkDK9SVzWUZA9JUMMOHfTjS3J4FwXDV6oasRKAV8yg9bL8","name":"CellCure Neurosciences","oneliner":"Cell Therapies for Neural Degenerative Diseases","registrar":"513752394","website":"https://lineagecell.com/manufacturing/","careerspage":"https://lineagecell.com/company/careers","founded_month":11,"founded_year":2005,"formernames":[],"sociallinks":{"twitter":"","youtube":"","facebook":"","linkedin":"https://www.linkedin.com/company/10231887","instagram":""},"social":["https://www.linkedin.com/company/10231887"],"flattenedsociallinks":"https://www.linkedin.com/company/10231887","apps":{"appstore":"","googleplay":""},"is_claimed_by_owner":null,"employees":"11-50","employees_exact":43,"patent":1,"raised":21790000,"stage":"Seed","public_stage":"Seed","primary_sector_key":"agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","primary_sector":"Health Tech & Life Sciences","alternativenames":["CellCure","lineagecell","Cell-Cure","Cell Cure"],"about":"Cell Cure Neurosciences is a biotechnology company developing cell therapies based on the use of human embryonic stem cells for the treatment of retinal and neural degenerative diseases. The company uses these powerful stem cells to manufacture the retinal pigment epithelial (RPE) cell.\n\nCell Cure’s first product in development, OpRegen, contains hESC-derived RPE cells to treat age-related macular degeneration (AMD). OpRegen is being developed as a frontline therapy for the dry form of AMD, which affects approximately 90% of AMD patients. \n\nCell Cure is currently conducting a phase 1/2 clinical trial of OpRegen to treat the larger market of dry AMD, for which there is currently no FDA-approved therapeutic. The company has recently completed construction of a cGMP manufacturing facility for the production of OpRegen and other cell therapy products.\n\nCell Cure Neurosciences is a fully owned subsidiary of California-based Lineage Cell Therapeutics, formerly BioTime.","climatetech_description":null,"is_climatetech_relevant":null,"phone":"+97225722000","country":null,"address":{"israeli":[{"id":"078913ed-bf13-4d2f-9c16-da1abce3758a","city":"Jerusalem","type":null,"address":"Hadassah Ein Kerem, Jerusalem, Israel","placeid":null,"notactive":0,"openeddate":null,"registrarid":null,"firstrdcenter":0,"registrarname":null}],"officesabroad":null},"headquarter_address":null,"district":"Jerusalem District","news":[{"id":"1f82bf9b-6d86-4924-ac44-feb6ef63a3f0","date":"Dec 20, 2021","link":"https://www.businesswire.com/news/home/20211220005028/en/Lineage-Establishes-Exclusive-Worldwide-Collaboration-With-Genentech-for-the-Development-and-Commercialization-of-OpRegen%C2%AE-RPE-Cell-Therapy-for-the-Treatment-of-Ocular-Disorders","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"6brGtgKuZmpmlOnMhHmnIIsx97vWmzLSGzWvd6NpbC8KMFgZN2pCF3","news_summary":"Lineage Establishes Exclusive Worldwide Collaboration With Genentech for the Development and Commercialization of OpRegen® RPE Cell Therapy for the Treatment of Ocular Disorders","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"e8f58c03-eada-4366-a0dc-9e0fc7556b1c","date":"May 10, 2019","link":"https://www.businesswire.com/news/home/20190510005103/en/BioTime-Awarded-2.5-Million-Grant-Israel-Innovation","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"tfNO8HvWhfBDxPTY844alXcG6ZGgpwWWVeXzoQzWG3llRJm3aA3uyl","news_summary":"BioTime Awarded $2.5 Million Grant from the Israel Innovation Authority for Continued Development of OpRegen®","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"c70443e7-c0a6-426c-a4c0-f423d93f0a76","date":"Jun 18, 2017","link":"https://en.globes.co.il/en/article-hadasit-sells-stem-cell-co-cellcure-stake-1001193059","source":"en.globes.co.il","visible":1,"analysis":{"tags":"investment","company":"Hadasit Bio-Holdings Ltd.","layoffs":null,"summary":"Hadasit Bio-Holdings has sold its 21% stake in Cell Cure to BioTime for $12.75 million. The deal reflects a $60 million value for Cell Cure, a stem cell company developing treatments for retinal degeneration. Hadasit believes it will post a $9 million pre-tax accounting profit following the deal. BioTime already owns 62% of Cell Cure and will have full ownership after the deal. BioTime has given Hadasit a five-year option to buy back 5% of Cell Cure. The announcement caused Hadasits share price to jump 35%.","partners":null,"customers":null,"investors":"BioTime Inc.","confidence":9,"key_topics":["Cell Cure","BioTime","stem cell implants","retinal degeneration","Hadasit Bio-Holdings"],"date_of_event":"June 18, 2017","valuation_amount":"$60 million","impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"Rc0hbgKprOcZEWkfgdFWNdMLSxP15X8hypleS9mmuOTFlkPih8XcUN","news_summary":"Hadasit sells stem cell co Cell Cure stake","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"2c1dd37d-d599-414e-918d-f7c0d6bd1cfb","date":"Sep 6, 2015","link":"http://www.globes.co.il/en/article-us-co-biotime-dual-listing-on-tase-1001066549","source":"www.globes.co.il","visible":1,"analysis":{"tags":"Dual Listing, Biotechnology","company":"BioTime, Inc.","layoffs":"Not mentioned","summary":"US biotechnology company, BioTime, Inc., is set to dual list on the Tel Aviv Stock Exchange. The company, which has a market cap of $268 million, will be traded under the ticker symbol BTX. BioTime CEO, Michael West, believes that the dual listing will help the company to open a new access point for their shares in the Israeli market and expand and diversify their shareholder base. The company has two Israeli subsidiaries, Cell Cure Neurosciences Ltd. and LifeMap Sciences Ltd.","partners":"Weizmann Institute of Science, Hadassah Human Embryonic Stem Cell Research Center at Hadassah University Medical Center","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":["Dual Listing","Cell-based Therapies","Israeli Market","Shareholder Base","Clinical Trial"],"date_of_event":"September 8, 2015","valuation_amount":"$268 million","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Public Trading","Expand"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Public Trading  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"OwKQ8NjUUs5uaFm4FPdPJsQZnVOs9X5AZgTRHc6xtaR7grC9mfieRq","news_summary":"US co BioTime dual-listing on TASE","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"4c0000e6-c459-43b5-87e5-00c25f8bcd6d","date":"Feb 17, 2015","link":"http://www.businesswire.com/news/home/20150217005417/en/Cell-Cure-Neurosciences-Ltd.-Update-Product-Development#.VOrwzPmUePs","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"ahYhy02OOYUApvu48TwSVkOAGo5r3RGMvxIvF7uHGNE0Vw4ES8OJhM","news_summary":"Cell Cure Neurosciences Ltd. Provides Update on its Product Development and Partnering Activities","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"bf4ecf0f-9124-452f-99db-2fdf0329953b","date":"May 16, 2013","link":"http://www.globes.co.il/en/article-1000844426","source":"www.globes.co.il","visible":1,"analysis":{"tags":"stem cell, therapeutic cells, retinal degenerative disease, neural degenerative disease, grant, OpRegen, age-related macular degeneration","company":"Cell Cure","layoffs":null,"summary":"Stem cell company Cell Cure Neurosciences has been awarded a NIS 5.34 million grant for the development of OpRegen, a cell-based therapeutic product for the treatment of age-related macular degeneration. The company plans to complete preclinical testing and file an application for human clinical trials in 2014. Cell Cure is developing therapeutic cells for the treatment of retinal and neural degenerative disease. The company was acquired by BioTime in 2010 and has received investments from BioTime, Teva Pharmaceutical Industries Ltd., and Hadasit Bio Holdings Ltd.","partners":["BioTime","Teva Pharmaceutical Industries Ltd.","Hadasit Bio Holdings Ltd."],"customers":null,"investors":["Israels Chief Scientist at the Ministry of the Economy"],"confidence":9,"key_topics":["Stem cell","Therapeutic cells","Grant","OpRegen","Age-related macular degeneration"],"date_of_event":"May 16, 2013","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"NIS 5.34 million","structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"aETM4HAlMjGEtCPMRVENaOW5wo8PT2Bd10H0FiBjYwydaI09gqZhDM","news_summary":"Cell Cure Neurosciences awarded $1.5m Chief Scientist grant","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"30886812-ed9d-4335-97e8-bbb3b297e2be","date":"Oct 10, 2010","link":"https://en.globes.co.il/en/article-1000593040","source":"en.globes.co.il","visible":1,"analysis":{"tags":"investment","company":"CellCure Neurosciences Ltd.","layoffs":null,"summary":"CellCure Neurosciences Ltd., a stem cell company, has raised $7.1 million in a funding round. Teva Pharmaceutical Industries Ltd., BioTime Inc., and Hadasit Bio Holdings Ltd. are among the investors. Teva will receive rights to CellCures AMD eye disease treatment and will invest $2 million immediately. BioTime is the biggest investor in the round, contributing $4.1 million. Hadasit also invested $1 million and converted its previous loan into equity. This funding round marks the largest ever for CellCure and the first commercial agreement for a Hadasit portfolio company. The event occurred on October 10, 2010.","partners":null,"customers":null,"investors":["Teva Pharmaceutical Industries Ltd.","BioTime Inc.","Hadasit Bio Holdings Ltd."],"confidence":9,"key_topics":["investment","AMD eye disease treatment","funding round","commercial agreement","Hadasit Bio Holdings Ltd."],"date_of_event":"2010-10-10","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$7.1 million","structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"PRXGihPrj6ZmfMoyK3lVVH8hNUgForyvt8lXWCk3ytq02go40oPPzq","news_summary":"Stem cell co CellCure raises $7.1m","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"}],"newsNumber":7,"techcommunityinvolvement":null,"mediagallery":[],"tags":["regenerative-medicine","degenerative-diseases","neurology","cell-therapy","eye-diseases","stem-cells","biotechnology","ophthalmology","medical-technologies","treatments"],"classificationIDs":["agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IeQo-oIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4MeNluQIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7vMIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA"],"technologysuccessstory":[{"date":"2005-11-01","name":"Cell Therapies for Neural Degenerative Diseases","tags":["degenerative-diseases","cell-therapy","stem-cells","eye-diseases","treatments"],"category":"Life Sciences & Biotechnology","tto_logo":"/image_cloud/hadasit_tto_logo_e7d2a863-6016-11e8-a626-41fdcbb0dda7","university_logo":"/image_cloud/hadasit_institution_logo_e7d2a863-6016-11e8-a626-41fdcbb0dda6"}],"usecases":[],"businessmodels":["B2C"],"productstage":"Clinical Trial","products":["OpRegen","OPC1","VAC2"],"geomarkets":["United States"],"targetmarkets":[],"marketcapital":null,"marketcapitaldate":null,"funding":{"investors":3,"lastfunding":"$2.5M","totalrounds":9,"fundingstage":"Seed","totalfunding":"$21.79M","publicinvestors":3,"lastpublicfunding":2500000,"totalpublicrounds":9,"totalpublicfunding":21790000},"team":[{"name":"Dr. Rami Skaliter","email":"Rami@cellcure.co.il","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAoND5-MkKDA","bounced":false,"claimed":0,"founder":0,"urlname":"dr-rami-skaliter","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICgkKWusQoM","position":"CEO","last_name":"Skaliter","claimtoken":"BPHozIg73NFrdtX7H7uDb6fjHJn2mYR5JVflDl97OWexRVgXQvW2Ot","first_name":"Dr. Rami","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/rami-skaliter-22313a1a/","unsubscribed":false,"is_activeuser":0,"additionalemail":" skaliter","claimedemaildate":"2022-12-20 11:36:15.000000","initials":"DS","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Sara Altman","email":"sara@cellcure.co.il","phone":"","gender":"Female","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgJ7G390JDA","bounced":false,"claimed":null,"founder":0,"urlname":"sara-altman","visible":1,"memberid":"mBGnlAVfP3WL8KKP4ABDtLUfcQ86icGyihbzHwdXVub4QxskJG2q50","position":"CFO","last_name":"Altman","claimtoken":"GF856inr1TPsSGcaEBE4anJXkdkuY5oLqUFbyEh3yn2cu4AiCGyhRE","first_name":"Sara","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/sara-altman-05b3038a/","unsubscribed":false,"is_activeuser":0,"additionalemail":"","claimedemaildate":"2022-12-20 11:42:29.000000","initials":"SA","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Prof. Benjamin Reubinoff","email":"benjamin@cellcureneurosciences.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4MKm6OgIDA","bounced":true,"claimed":0,"founder":0,"urlname":"prof-benjamin-reubinoff","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDg3K7RjwoM","position":"CSO","last_name":"Reubinoff","claimtoken":"c33dd8fd840e1e65824c6dc08a19f831042068281fa1321e513bb4f0b308e57a","first_name":"Prof. Benjamin","picturekey":null,"claimeddate":null,"linkedinurl":null,"unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2020-10-14 13:27:53.000000","initials":"PR","pictureurl":"/assets/empty-state.svg","linkedin-display":"none","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Dana Hayoun-Neeman","email":"dana@cellcure.co.il","phone":"","gender":"Female","userid":"wecNQx5IwJL0HbPt5viL89tYwqZfqY8pZjafXVPr3u6NCrUnd3GZID","bounced":false,"claimed":null,"founder":0,"urlname":"dana-hayoun-neeman","visible":1,"memberid":"UD7tMXz1OC0Qiqz2QpJ7WMCRtQInqCQwaRIjMNye9fLXcToeVKBTsI","position":"VP R&D","last_name":"Hayoun-Neeman","claimtoken":"1N84Z6HlwWQAwBfa9MXe0qzQX93Z6sAV0IyXMYTRGdpxMwtAKqlkPQ","first_name":"Dana","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/dana-hayoun-neeman-2598762b/","unsubscribed":false,"is_activeuser":0,"additionalemail":"","claimedemaildate":"2022-12-20 11:42:33.000000","initials":"DH","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""}],"description_edited":1,"tag_line_edited":1,"sector":"Digital Health and Medical Technologies","sectorverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgLHD0KwIDA","fullname":"Sharon Shapira"},"biverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgLHD0KwIDA","fullname":"Sharon Shapira"},"biverifydate":"2020-01-19T00:00:00.000Z","crunchbaseid":"cell-cure-neurosciences","lastupdator":"Matan Eblagon","lastupdator_email":"matane@sncentral.org","creator":"Rebecca Mack","creator_email":"rebeccamack26@gmail.com","createdate":"2014-07-30T00:00:00.000Z","biverification":"Sharon Shapira","sectorverification":"Sharon Shapira","affiliatedOrganizations":null,"timeline":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCCjaGcCww","date":"May 2019","amount":"$2.5M","source":"https://www.businesswire.com/news/home/20190510005103/en/BioTime-Awarded-2.5-Million-Grant-Israel-Innovation, https://www.israel21c.org/12-revolutionary-advances-for-your-eye-health/","eventtype":"GrantEvent","granttype":1,"investment":[{"name":"Israel Innovation Authority","type":"Government","amount":0,"hidden":false,"country":"Israel","fullurl":"/company_page/israel-innovation-authority-4","logokey":"$5c4LgWLzukZDi2b9IlcK1cbez0QSOoXpTLU21Y4ByNtfkRvqOSLs8L","tagline":"","urlname":"/company_page/israel-innovation-authority-4","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOC20eTwCQw","fundingtype":"Government","leadpartner":null,"investmentid":"7f7089c4-614e-42a4-9134-b5a0a4d1a697","fundingsubtype":"","investorislead":0,"amountvisibility":"Public","isextensionround":null,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$5c4LgWLzukZDi2b9IlcK1cbez0QSOoXpTLU21Y4ByNtfkRvqOSLs8L","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"isjointventuregrant":0,"style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Non-Equity Funding","isgrant":true,"isicoevent":false,"amountnumber":2500000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOD42-yWCAw","date":"Jun 2016","amount":"$2.2M","source":"Added by Daniela Gehtaman","eventtype":"GrantEvent","granttype":1,"investment":[{"name":"Israel Innovation Authority","type":"Government","amount":0,"hidden":false,"country":"Israel","fullurl":"/company_page/israel-innovation-authority-4","logokey":"$5c4LgWLzukZDi2b9IlcK1cbez0QSOoXpTLU21Y4ByNtfkRvqOSLs8L","tagline":"","urlname":"/company_page/israel-innovation-authority-4","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOC20eTwCQw","fundingtype":"Government","leadpartner":null,"investmentid":"5440b8e6-814b-4caa-b9a9-3bbc77d7c532","fundingsubtype":"","investorislead":null,"amountvisibility":"Public","isextensionround":null,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$5c4LgWLzukZDi2b9IlcK1cbez0QSOoXpTLU21Y4ByNtfkRvqOSLs8L","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"isjointventuregrant":0,"fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Non-Equity Funding","isgrant":true,"isicoevent":false,"amountnumber":2200000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODY5Y3CCAw","date":"May 2015","amount":"$1.6M","source":"Added by Daniela Gehtaman","eventtype":"GrantEvent","granttype":0,"investment":[],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"isjointventuregrant":0,"fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Non-Equity Funding","isgrant":true,"isicoevent":false,"amountnumber":1600000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODkwNbNCQw","date":"Dec 2013","amount":"$1.74M","source":"Added by Daniela Gehtaman","eventtype":"GrantEvent","granttype":1,"investment":[{"name":"Office of the Chief Scientist","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/office-of-the-chief-scientist","logokey":null,"tagline":"","urlname":"/investor_page/office-of-the-chief-scientist","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCEv8qRCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"bb349471-c86d-467a-afbd-7ec83c2dd934","fundingsubtype":"VC and Private Equity","investorislead":null,"amountvisibility":"Public","isextensionround":null,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"isjointventuregrant":0,"fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Non-Equity Funding","isgrant":true,"isicoevent":false,"amountnumber":1740000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCEzZigCAw","date":"May 2013","amount":"$1.5M","source":"Added by Daniela Gehtaman","eventtype":"GrantEvent","granttype":1,"investment":[{"name":"Office of the Chief Scientist","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/office-of-the-chief-scientist","logokey":null,"tagline":"","urlname":"/investor_page/office-of-the-chief-scientist","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCEv8qRCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"53d0279c-1318-4107-bc03-f93ee4e9b943","fundingsubtype":"VC and Private Equity","investorislead":null,"amountvisibility":"Public","isextensionround":null,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"isjointventuregrant":0,"fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Non-Equity Funding","isgrant":true,"isicoevent":false,"amountnumber":1500000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCko9LqCww","date":"Nov 2012","amount":"$3.5M","source":"Migrated","eventtype":"FundingRoundEvent","investment":[{"name":"BioTime Inc.","type":"Other","amount":0,"hidden":false,"country":"United States","fullurl":"/company_page/biotime-inc","logokey":"$1pR2fxmUWnqjGfhc4A8kRzfqzQrcrS0iADW09SEEsR97FUKljZGGbP","tagline":"","urlname":"/company_page/biotime-inc","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCkmqncCgw","fundingtype":"Other","leadpartner":null,"investmentid":"ad6ed640-372b-42ad-8d24-d5f8940f47b0","fundingsubtype":"","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$1pR2fxmUWnqjGfhc4A8kRzfqzQrcrS0iADW09SEEsR97FUKljZGGbP","leadcaption":"","followupcaption":"Follow on "}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Undisclosed Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":3500000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOD428uxCQw","date":"Oct 2010","amount":"$7.1M","source":"Migrated","eventtype":"FundingRoundEvent","investment":[{"name":"BioTime Inc.","type":"Other","amount":0,"hidden":false,"country":"United States","fullurl":"/company_page/biotime-inc","logokey":"$1pR2fxmUWnqjGfhc4A8kRzfqzQrcrS0iADW09SEEsR97FUKljZGGbP","tagline":"","urlname":"/company_page/biotime-inc","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCkmqncCgw","fundingtype":"Other","leadpartner":null,"investmentid":"22ee3c81-6537-4632-8f1a-3416f2527adf","fundingsubtype":"","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$1pR2fxmUWnqjGfhc4A8kRzfqzQrcrS0iADW09SEEsR97FUKljZGGbP","leadcaption":"","followupcaption":""},{"name":"Hadasit Bio-Holdings","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/hadasit-bio-holdings","logokey":"$kZnxCaWkMvHvbb7PRLE5W0kSpoB1D90OVXE4NfoD2w8XliSYFvD2nu","tagline":null,"urlname":"/investor_page/hadasit-bio-holdings","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwPH6jtIJDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"e3827118-1af2-4843-bfe9-039bbdf06e98","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$kZnxCaWkMvHvbb7PRLE5W0kSpoB1D90OVXE4NfoD2w8XliSYFvD2nu","leadcaption":"","followupcaption":"Follow on "},{"name":"Teva Pharmaceuticals","type":"Startup","amount":0,"hidden":false,"country":"Israel","fullurl":"/company_page/teva","logokey":"$CwlOg6rRZ3iO6aLvYtiGncAnQsFuidOs9Ih1NGesAyDIy4aAHL2zxN","tagline":"Generic and Specialty Pharmaceuticals","urlname":"/company_page/teva","isisraeli":null,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgL6R05IJDA","fundingtype":"Startup","leadpartner":null,"investmentid":"eda47bfe-e92f-4cce-aeee-adf450d6d76a","fundingsubtype":"","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$CwlOg6rRZ3iO6aLvYtiGncAnQsFuidOs9Ih1NGesAyDIy4aAHL2zxN","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Undisclosed Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":7100000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODEtaG9Cgw","date":"Oct 2009","amount":"$1M","source":"https://en.globes.co.il/en/article-1000593040","eventtype":"FundingRoundEvent","investment":[{"name":"Hadasit Bio-Holdings","type":"Investor","amount":1000000,"hidden":false,"country":"Israel","fullurl":"/investor_page/hadasit-bio-holdings","logokey":"$kZnxCaWkMvHvbb7PRLE5W0kSpoB1D90OVXE4NfoD2w8XliSYFvD2nu","tagline":null,"urlname":"/investor_page/hadasit-bio-holdings","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwPH6jtIJDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"cd76ac7e-14eb-4442-82df-829861e38caa","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$kZnxCaWkMvHvbb7PRLE5W0kSpoB1D90OVXE4NfoD2w8XliSYFvD2nu","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Convertible Debt","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":1000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCko9KKCww","date":"Jan 2009","amount":"$650K","source":"Added by Daniela Gehtaman","eventtype":"GrantEvent","granttype":0,"investment":[{"name":"The Michael J. Fox Foundation for Parkinson's Research","type":"Other","amount":0,"hidden":false,"country":"United States","fullurl":"/company_page/the-michael-j-fox-foundation-for-parkinsons-research","logokey":"$MG1CcnBPlSWoYv20w1ZUJSxGkrScLrzvzi7cbWqRfAIMIw1J4SYu5l","tagline":"","urlname":"/company_page/the-michael-j-fox-foundation-for-parkinsons-research","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCEyJmcCQw","fundingtype":"Other","leadpartner":null,"investmentid":"ea480794-fef4-429c-84e6-ad7821a4e645","fundingsubtype":"","investorislead":null,"amountvisibility":"Public","isextensionround":null,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$MG1CcnBPlSWoYv20w1ZUJSxGkrScLrzvzi7cbWqRfAIMIw1J4SYu5l","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"isjointventuregrant":0,"fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Non-Equity Funding","isgrant":true,"isicoevent":false,"amountnumber":650000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"investmentstage":[],"exits":[],"investments":[],"portfolio":[],"funds":[],"founded":"11/2005","databases":[],"sharedspaces":[],"utilities":[],"contributors":[],"employeesworldwide":"","fundingtype":"Startup","parsedName":"CellCure Neurosciences","logourl":"https://storage.googleapis.com/clean-finder-353810/$YN0LZm3MrkDK9SVzWUZA9JUMMOHfTjS3J4FwXDV6oasRKAV8yg9bL8","oglogourl":"https://storage.googleapis.com/clean-finder-353810/$YN0LZm3MrkDK9SVzWUZA9JUMMOHfTjS3J4FwXDV6oasRKAV8yg9bL8","seoabout":"Cell Cure Neurosciences is a biotechnology company developing cell therapies based on the use of human embryonic stem cells for the treatment of retinal an...","seoTitle":"Israeli Startup","solutions":[],"teamMembersNumber":4,"primarySector":"Health Tech & Life Sciences","primary-sector-display":"block","classifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Biomaterials & Tissue Engineering","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4MeNluQIDA","classificationName":"sectorclassification"},{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"},{"depth":2,"name":"Cells","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7vMIDA","classificationName":"coretechnology"},{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Biotechnology","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IeQo-oIDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"},{"depth":2,"name":"Healthcare","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","classificationName":"targetcustomer"}],"classificationDelimited":["SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA>Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IeQo-oIDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA>Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA>Biomaterials & Tissue Engineering#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4MeNluQIDA","TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA>Cells#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7vMIDA","TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA"],"classificationsViewModel":"|0:>SectorClassificationModel|1:>SectorClassificationModel/Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA|2:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA/Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA/Biomaterials & Tissue Engineering#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4MeNluQIDA|0:>IndustryClassificationModel|1:>IndustryClassificationModel/Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA/Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IeQo-oIDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA/Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA|0:>TechnologyClassificationModel|1:>TechnologyClassificationModel/Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA|2:>TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA/Cells#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7vMIDA|","classificationTrees":{"sector":[{"title":"Health Tech & Life Sciences","key":"0-0","path":"SectorClassificationModel>Health Tech & Life Sciences","children":[{"title":"Pharma & Medical Biotechnology","key":"0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology","children":[{"title":"Biomaterials & Tissue Engineering","key":"0-0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology>Biomaterials & Tissue Engineering"}]}]}],"targetCustomer":[{"title":"Healthcare & Life Sciences","key":"0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences","children":[{"title":"Life Sciences","key":"0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences","children":[{"title":"Biotechnology","key":"0-0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences>Biotechnology"},{"title":"Pharmaceuticals","key":"0-0-0-1","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences>Pharmaceuticals"}]},{"title":"Healthcare","key":"0-0-1","path":"IndustryClassificationModel>Healthcare & Life Sciences>Healthcare"}]}],"coreTechnology":[{"title":"Biologicals","key":"0-0","path":"TechnologyClassificationModel>Biologicals","children":[{"title":"Cells","key":"0-0-0","path":"TechnologyClassificationModel>Biologicals>Cells"}]}]},"sectorClassifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Biomaterials & Tissue Engineering","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4MeNluQIDA","classificationName":"sectorclassification"}],"coreTechnologyClassifications":[{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"},{"depth":2,"name":"Cells","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7vMIDA","classificationName":"coretechnology"}],"targetCustomerClassifications":[{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Biotechnology","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IeQo-oIDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"},{"depth":2,"name":"Healthcare","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","classificationName":"targetcustomer"}],"classificationNames":{"sector":["Health Tech & Life Sciences","Pharma & Medical Biotechnology","Biomaterials & Tissue Engineering"],"coreTechnology":["Biologicals","Cells"],"targetCustomer":["Healthcare & Life Sciences","Life Sciences","Biotechnology","Pharmaceuticals","Healthcare"]},"section":null,"sectionParams":"","queryParams":"","popup_claim_profile":"false","claimedBadge":"none","display":{"mainContact":"none","climateTag":"none","seeMoreSimilarCompanisDisplay":"none","similarCompaniesTitleFontSize":"3.2rem","similarCompaniesTitle":"Similar Companies","similar_companies":[]},"mainContact":{},"_eventview":{"publicoffering_exit":[],"privateequityfunding":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCko9LqCww","date":"Nov 2012","amount":"$3.5M","source":"Migrated","eventtype":"FundingRoundEvent","investment":[{"name":"BioTime Inc.","type":"Other","amount":0,"hidden":false,"country":"United States","fullurl":"/company_page/biotime-inc","logokey":"$1pR2fxmUWnqjGfhc4A8kRzfqzQrcrS0iADW09SEEsR97FUKljZGGbP","tagline":"","urlname":"/company_page/biotime-inc","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCkmqncCgw","fundingtype":"Other","leadpartner":null,"investmentid":"ad6ed640-372b-42ad-8d24-d5f8940f47b0","fundingsubtype":"","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$1pR2fxmUWnqjGfhc4A8kRzfqzQrcrS0iADW09SEEsR97FUKljZGGbP","leadcaption":"","followupcaption":"Follow on "}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Undisclosed Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":3500000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOD428uxCQw","date":"Oct 2010","amount":"$7.1M","source":"Migrated","eventtype":"FundingRoundEvent","investment":[{"name":"BioTime Inc.","type":"Other","amount":0,"hidden":false,"country":"United States","fullurl":"/company_page/biotime-inc","logokey":"$1pR2fxmUWnqjGfhc4A8kRzfqzQrcrS0iADW09SEEsR97FUKljZGGbP","tagline":"","urlname":"/company_page/biotime-inc","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCkmqncCgw","fundingtype":"Other","leadpartner":null,"investmentid":"22ee3c81-6537-4632-8f1a-3416f2527adf","fundingsubtype":"","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$1pR2fxmUWnqjGfhc4A8kRzfqzQrcrS0iADW09SEEsR97FUKljZGGbP","leadcaption":"","followupcaption":""},{"name":"Hadasit Bio-Holdings","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/hadasit-bio-holdings","logokey":"$kZnxCaWkMvHvbb7PRLE5W0kSpoB1D90OVXE4NfoD2w8XliSYFvD2nu","tagline":null,"urlname":"/investor_page/hadasit-bio-holdings","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwPH6jtIJDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"e3827118-1af2-4843-bfe9-039bbdf06e98","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$kZnxCaWkMvHvbb7PRLE5W0kSpoB1D90OVXE4NfoD2w8XliSYFvD2nu","leadcaption":"","followupcaption":"Follow on "},{"name":"Teva Pharmaceuticals","type":"Startup","amount":0,"hidden":false,"country":"Israel","fullurl":"/company_page/teva","logokey":"$CwlOg6rRZ3iO6aLvYtiGncAnQsFuidOs9Ih1NGesAyDIy4aAHL2zxN","tagline":"Generic and Specialty Pharmaceuticals","urlname":"/company_page/teva","isisraeli":null,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgL6R05IJDA","fundingtype":"Startup","leadpartner":null,"investmentid":"eda47bfe-e92f-4cce-aeee-adf450d6d76a","fundingsubtype":"","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$CwlOg6rRZ3iO6aLvYtiGncAnQsFuidOs9Ih1NGesAyDIy4aAHL2zxN","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Undisclosed Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":7100000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODEtaG9Cgw","date":"Oct 2009","amount":"$1M","source":"https://en.globes.co.il/en/article-1000593040","eventtype":"FundingRoundEvent","investment":[{"name":"Hadasit Bio-Holdings","type":"Investor","amount":1000000,"hidden":false,"country":"Israel","fullurl":"/investor_page/hadasit-bio-holdings","logokey":"$kZnxCaWkMvHvbb7PRLE5W0kSpoB1D90OVXE4NfoD2w8XliSYFvD2nu","tagline":null,"urlname":"/investor_page/hadasit-bio-holdings","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwPH6jtIJDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"cd76ac7e-14eb-4442-82df-829861e38caa","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$kZnxCaWkMvHvbb7PRLE5W0kSpoB1D90OVXE4NfoD2w8XliSYFvD2nu","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Convertible Debt","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":1000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"nonequityfunding":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCCjaGcCww","date":"May 2019","amount":"$2.5M","source":"https://www.businesswire.com/news/home/20190510005103/en/BioTime-Awarded-2.5-Million-Grant-Israel-Innovation, https://www.israel21c.org/12-revolutionary-advances-for-your-eye-health/","eventtype":"GrantEvent","granttype":1,"investment":[{"name":"Israel Innovation Authority","type":"Government","amount":0,"hidden":false,"country":"Israel","fullurl":"/company_page/israel-innovation-authority-4","logokey":"$5c4LgWLzukZDi2b9IlcK1cbez0QSOoXpTLU21Y4ByNtfkRvqOSLs8L","tagline":"","urlname":"/company_page/israel-innovation-authority-4","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOC20eTwCQw","fundingtype":"Government","leadpartner":null,"investmentid":"7f7089c4-614e-42a4-9134-b5a0a4d1a697","fundingsubtype":"","investorislead":0,"amountvisibility":"Public","isextensionround":null,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$5c4LgWLzukZDi2b9IlcK1cbez0QSOoXpTLU21Y4ByNtfkRvqOSLs8L","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"isjointventuregrant":0,"style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Non-Equity Funding","isgrant":true,"isicoevent":false,"amountnumber":2500000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOD42-yWCAw","date":"Jun 2016","amount":"$2.2M","source":"Added by Daniela Gehtaman","eventtype":"GrantEvent","granttype":1,"investment":[{"name":"Israel Innovation Authority","type":"Government","amount":0,"hidden":false,"country":"Israel","fullurl":"/company_page/israel-innovation-authority-4","logokey":"$5c4LgWLzukZDi2b9IlcK1cbez0QSOoXpTLU21Y4ByNtfkRvqOSLs8L","tagline":"","urlname":"/company_page/israel-innovation-authority-4","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOC20eTwCQw","fundingtype":"Government","leadpartner":null,"investmentid":"5440b8e6-814b-4caa-b9a9-3bbc77d7c532","fundingsubtype":"","investorislead":null,"amountvisibility":"Public","isextensionround":null,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$5c4LgWLzukZDi2b9IlcK1cbez0QSOoXpTLU21Y4ByNtfkRvqOSLs8L","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"isjointventuregrant":0,"fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Non-Equity Funding","isgrant":true,"isicoevent":false,"amountnumber":2200000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODY5Y3CCAw","date":"May 2015","amount":"$1.6M","source":"Added by Daniela Gehtaman","eventtype":"GrantEvent","granttype":0,"investment":[],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"isjointventuregrant":0,"fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Non-Equity Funding","isgrant":true,"isicoevent":false,"amountnumber":1600000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODkwNbNCQw","date":"Dec 2013","amount":"$1.74M","source":"Added by Daniela Gehtaman","eventtype":"GrantEvent","granttype":1,"investment":[{"name":"Office of the Chief Scientist","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/office-of-the-chief-scientist","logokey":null,"tagline":"","urlname":"/investor_page/office-of-the-chief-scientist","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCEv8qRCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"bb349471-c86d-467a-afbd-7ec83c2dd934","fundingsubtype":"VC and Private Equity","investorislead":null,"amountvisibility":"Public","isextensionround":null,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"isjointventuregrant":0,"fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Non-Equity Funding","isgrant":true,"isicoevent":false,"amountnumber":1740000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCEzZigCAw","date":"May 2013","amount":"$1.5M","source":"Added by Daniela Gehtaman","eventtype":"GrantEvent","granttype":1,"investment":[{"name":"Office of the Chief Scientist","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/office-of-the-chief-scientist","logokey":null,"tagline":"","urlname":"/investor_page/office-of-the-chief-scientist","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCEv8qRCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"53d0279c-1318-4107-bc03-f93ee4e9b943","fundingsubtype":"VC and Private Equity","investorislead":null,"amountvisibility":"Public","isextensionround":null,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"isjointventuregrant":0,"fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Non-Equity Funding","isgrant":true,"isicoevent":false,"amountnumber":1500000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCko9KKCww","date":"Jan 2009","amount":"$650K","source":"Added by Daniela Gehtaman","eventtype":"GrantEvent","granttype":0,"investment":[{"name":"The Michael J. Fox Foundation for Parkinson's Research","type":"Other","amount":0,"hidden":false,"country":"United States","fullurl":"/company_page/the-michael-j-fox-foundation-for-parkinsons-research","logokey":"$MG1CcnBPlSWoYv20w1ZUJSxGkrScLrzvzi7cbWqRfAIMIw1J4SYu5l","tagline":"","urlname":"/company_page/the-michael-j-fox-foundation-for-parkinsons-research","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCEyJmcCQw","fundingtype":"Other","leadpartner":null,"investmentid":"ea480794-fef4-429c-84e6-ad7821a4e645","fundingsubtype":"","investorislead":null,"amountvisibility":"Public","isextensionround":null,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$MG1CcnBPlSWoYv20w1ZUJSxGkrScLrzvzi7cbWqRfAIMIw1J4SYu5l","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"isjointventuregrant":0,"fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Non-Equity Funding","isgrant":true,"isicoevent":false,"amountnumber":650000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"merger_acquisitions":[],"others":[]}}